Italia markets closed

AbbVie Inc. (0QCV.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
89,63+9,15 (+11,37%)
Alla chiusura: 11:39AM GMT

AbbVie Inc.

1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
http://www.abbvie.com

Settore/i
Settore
Impiegati a tempo pieno48.000

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Richard A. GonzalezChairman & CEO7,36M7,76M1954
Dr. Michael E. SeverinoVice Chairman & Pres4,29MN/D1966
Mr. Robert A. MichaelExec. VP & CFO3,22MN/D1970
Ms. Laura J. SchumacherVice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.4,2MN/D1963
Dr. Azita Saleki-GerhardtExec. VP of OperationsN/DN/D1963
Dr. Thomas J. HudsonSr. VP of R&D and Chief Scientific OfficerN/DN/D1962
Ms. Elizabeth SheaVP of Investor RelationsN/DN/DN/D
Mr. Timothy J. RichmondExec. VP & Chief HR OfficerN/DN/D1966
Mr. Henry O. GosebruchExec. VP & Chief Strategy OfficerN/DN/D1973
Mr. Jeffrey Ryan StewartExec. VP & Chief Commercial OfficerN/DN/D1969
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Governance aziendale

L'ISS Governance QualityScore di AbbVie Inc. al 26 settembre 2021 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 5; diritti degli azionisti: 9; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.